Of the genes mutated in cancer, RAS remains the most elusive to target. Recent technological advances and discoveries have greatly expanded our knowledge of the biology of oncogenic Ras and its role in cancer. As such, it has become apparent that a property that intimately accompanies RAS-driven tumorigenesis is the dependence of RAS mutant cells on a number of non-oncogenic signaling pathways. These dependencies arise as a means of adaptation to Ras-driven intracellular stresses and represent unique vulnerabilities of mutant RAS cancers. A number of studies have highlighted the dependence of mutant RAS cancers on the DNA damage response and identified the molecular pathways that mediate this process including signaling from wild-type Ras isoforms, ATR/Chk1, and DNA damage repair pathways. Here we review these findings, and discuss the combinatorial use of DNA damaging chemotherapy with blockade of wild-type H-and N-Ras signaling by farnesyltransferase inhibitors, Chk1 inhibitors, or small molecule targeting DNA damage repair as potential strategies through which the dependence of RAS cancers on the DNA damage response can be harnessed for therapeutic intervention.
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Background
Oncogenic mutations in RAS (KRAS, HRAS, and NRAS) are highly pervasive in human solid tumors with poor therapeutic outcomes, including carcinomas of the pancreas, colon, lung, and melanoma (1) . Deterring the malignant properties bestowed by RAS mutations is an imperative necessity in cancer therapy and a major focus of new pharmacological intervention efforts. Targeting oncogenic Ras, however, is a challenging task due to the nature of the mutations in the RAS genes and inherent difficulties in disrupting the mechanistic switches that determine Ras activation status (2) . Ras proteins cycle between active GTP-bound and inactive GDP-bound states. Beyond targeting hyper-stimulated Ras signaling, there has been a growing awareness that RAS-driven malignancies are heavily dependent on cellular processes that are non-oncogenic per se, but rather are co-opted to bolster tumorigenic fitness.
Although it is not fully understood how such non-oncogene dependencies arise, the current model holds that they are brought forth as a consequence of the inevitable stresses that oncogene expression imparts on cancer cells (eg. replicative, metabolic, oxidative stress) (3). Surviving such Ras-induced intracellular stresses demands adaptation through mechanisms that mitigate stress. As with all dependencies, the reliance of the evolving tumor on stress-coping mechanisms is also a weakness and offers a unique window of opportunity to specifically target cancer cells. Studies aimed at uncovering unique vulnerabilities of RAS-driven tumors have identified a number of genes that mediate mutant RAS cancer dependencies on stress mitigating mechanisms including proteotoxic stress (GATA2, APC/C), DNA damage (ATR, Chk1, CDC6, NEIL2, XRCC1, LIG3, POlb, CUX1, PARP1), mitotic stress (CDK4, PLK1, APC/C), energetic stress (COPI, GLUT1, GOT1, GLUD1, HK1/2, PFK1, LDHA,); and inflammation (TBK1, TAK1, GATA2) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Many of these genes are undruggable, however pharmacological inhibitors of TAK1, genes involved in mitigating DNA damage (Chk1), and mitotic stress (CDK4, PLK1) are available and at various stages of clinical testing. Approaches at targeting TAK1 and mitotic stress coping mechanisms are reviewed elsewhere (15) .
Here we describe the dependence of RAS cancers on pathways that mitigate DNA damage, and discuss pharmacological inhibitors of these pathways which are currently Ras expression is frequently associated with an activation of the DDR as evidenced by elevated DNA damage upon acute oncogenic Ras expression, activation of DNA damage checkpoints, and cell cycle arrest (1, 16) . DDR activation is thought to arise as an intracellular reaction to genotoxic stress that is directly induced by oncogenic Ras.
Several observations point to at least two routes through which oncogenic Ras can induce genotoxic stress. First, oncogenic Ras has been shown to induce production of reactive oxygen species (ROS) and increase oxidative damage to DNA ( Fig. 1) (17-21) .
Secondly, oncogenic Ras expression induces DNA hyper-replication stress, as defined by aberrations in the number of active replicons and alterations in DNA replication fork progression, leading to DNA damage at sites of active DNA replication (Fig. 1 ).
Excessive DNA damage triggers an anti-proliferative response, which is incompatible with cancer progression. As such, the continuous growth of cancer cells requires tempering DNA damage to a level that does not impair cancer cell proliferation. In Recent studies have begun to identify the relevant pathways regulating oncogenic Ras-induced activation of DNA damage checkpoints and have pointed to the ATR protein kinase pathway as a key mediator of this response (10, 22) . Oncogenic Ras expression led to an elevation in ATR activity and an enhanced dependence on ATR functionality for the maintenance of genomic stability on a per-cell-cycle basis (10) .
Recent work has demonstrated that oncogenic Ras can modulate the function of Chk1, the immediate effector of ATR. This study showed that oncogenic K-Ras engages the wild-type H-and N-Ras proteins to ensure optimal Chk1 activation ( (23). Another study found that inhibition of the alt-NHEJ pathway selectively sensitized KRAS mutant leukemic cells to cytotoxic agents (24) . Mutant K-Ras was shown to activate alt-NHEJ by upregulating DNA ligase III, poly (ADP-ribose) polymerase 1 (PARP1), and XRCC1. It remains to be elucidated whether additional DNA damage repair pathways are subject to regulation by oncogenic Ras.
Clinical-Translational Advances
The dependences of cancer cells on stress-coping mechanisms constitute vulnerabilities that can be exploited for therapeutic advantage. As these dependences are unique to cancer cells, exacerbating stress by either exogenous stress-inducing agents and/or inhibiting the stress coping mechanisms could selectively lead to stress overload and cancer cell death. The body of work demonstrating the heightened DNA repair capabilities of mutant Ras cells predicts that interference with these capabilities would render Ras tumors particularly vulnerable to DNA damage-inducing agents.
Strategies that exploit this concept are discussed below.
Combinatorial Chk1 inhibition and DNA-damaging chemotherapy
Due to the role of Chk1 in DDR activation, several Chk1 inhibitors have been developed for combinatorial use with DNA-damaging chemotherapeutic agents in order to potentiate their cytotoxic effects. Early Chk1 inhibitors lacked specificity and showed unfavorable pharmacokinetics and pharmacodynamics (25) . However, several selective Chk1 inhibitors (MK-8776, CHIR-124, AZD7762, LY2603618, SAR-020106, GDC0425, and GDC0575) have been developed (26) . In normal cells, or cancer cells with a functional p53, Chk1 inhibition can be partially compensated for by engagement of the ATM/Chk2/p53 pathway (27) .Therefore, mutations in p53, which occur in ~50% of all 
cancers, have been considered predictive of the efficacy of Chk1 inhibitors with DNA damaging agents. Pre-clinical work has provided evidence both in support of and against the usage of p53 mutational status as a biomarker for sensitivity to combinatorial Chk1 inhibition and DNA-damaging agents (28, 29) . We have found that in a panel of p53 mutant cancer cell lines and tumors, the efficacy of Chk1 inhibitors at sensitizing to DNA-damaging agents is determined by the KRAS mutational status (11).
A plausible explanation for this sensitization is that Chk1 is a critical component of the cellular adaptation to RAS-driven replicative stress. Consequently, the efficacy of pharmacological inhibition and RNAi-mediated approaches to suppress these pathways have selectively sensitized mutant RAS cells to DNA-damaging agents (8, 23, 24) .
Investigational compounds that target DNA damage repair proteins regulated by mutant RAS include inhibitors for PARP-1, as well as DNA ligase III and DNA glycosylase inhibitors. The latter are still in the preclinical phase whereas PARP-1 inhibitors are currently in clinical testing. These compounds represent potential combinational candidates to be utilized in conjunction with DNA-damaging agents (39, 40) .
Combinatorial wild type H/N-Ras inhibition and DNA-damaging chemotherapy
Recent work has defined a functional dependence of KRAS-driven tumors on wild-type H-and N-Ras for the activation of the DNA damage checkpoint (11) . Following previous work demonstrating that p90RSK and AKT kinases inactivate Chk1, this study 
targeted KRAS mutant tumors (43, 44) . Nonetheless, as H-and N-Ras farnesylation and signaling is robustly impaired by FTIs, and with the increasing awareness that the wild type H-and N-Ras isoforms play a pro-tumorigenic role in mutant KRAS tumors, a rational combination of FTIs with other therapies may improve their clinical utility.
Specifically, the dependence of mutant KRAS cancers on wild type H-Ras and N-Ras for Chk1 activation suggests that combinatorial strategies composed of FTIs and irinotecan or other DNA damaging agents, could prove therapeutically efficacious in the clinic. In support of this idea FTase inhibition selectively radiosensitized KRAS mutant cancer cell-lines and tumors (45, 46) . It is important to note that timing of dosing has been shown to be critical for the efficacy of combinatorial treatments with FTIs. As such, combination of the FTI SCH66336 with cisplatin only showed a supra-additive effect when SCH66336 administration preceded cisplatin treatment whereas co-administration of SCH66336 with cisplatin, or gemcitabine was strictly additive or less than additive (47) . Moreover, co-administration of gemcitabine and the FTI R115777 showed no statistically significant difference in median overall survival or progression-free survival compared to gemcitabine alone or placebo in a Phase III clinical trial in patients with advanced pancreatic adenocarcinoma (44) . Another important factor to consider in combining FTIs with DNA damaging agents are the functional properties of the latter.
FTI treatment of KRAS mutant tumors would in principle suppress wild type H/N-Ras function and lead to impaired Chk1 activity, and as previously discussed in this review, the sensitization capabilities of Chk1 inhibition can vary with different DNA damaging agents. Therefore, it might be necessary to pre-clinically define a combination schedule that will allow optimal therapeutic efficacy. As a cautionary note however, despite the 
Concluding Remarks
In sum, the dependence of RAS mutant cancers on processes that mitigate DNA damage occurs as a means of adaptation to Ras-induced genotoxic stress. The molecular pathways through which mutant Ras regulates these processes offer a number of potential drug targets and combinatorial therapies. Novel clinical approaches could consist of combinatorial regimens using existing therapeutic agents, such as Chk1/Wee1, FTI, or PARP-1 inhibitors, together with DNA-damaging agents.
Alternatively, drug development approaches could be centered on Ras-targets within the DNA damage repair pathway. Overall, the clinical challenges currently being faced in treating RAS-driven cancers clearly demonstrate a need for novel effective therapies that take advantage of the multifaceted biological reliances that are characteristic of these tumors.
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